Ahmadian Mehdi, Roshan Valiollah Dabidi, Aslani Elaheh, Stannard Stephen R
Department of Physical Education and Sport Sciences, Aliabad Katoul Branch, Islamic Azad University, Aliabad Katoul, Iran.
Department of Sport Physiology, College of Physical Education and Sport Sciences, University of Mazandaran (UMZ), Babolsar, Iran.
Ther Adv Cardiovasc Dis. 2017 Jul;11(7):185-194. doi: 10.1177/1753944717711138. Epub 2017 Jun 5.
The purpose of this study was to examine the anti-atherogenic and anti-inflammatory effect of supplemental taurine prior to and following incremental exercise in patients with heart failure (HF).
Patients with HF and left ventricle ejection fraction less than 50%, and placed in functional class II or III according to the New York Heart Association classification, were randomly assigned to two groups: (1) taurine supplementation; or (2) placebo. The taurine group received oral taurine (500 mg) 3 times a day for 2 weeks, and performed exercise before and after the supplementation period. The placebo group followed the same protocol, but with a starch supplement (500 mg) rather than taurine. The incremental multilevel treadmill test was done using a modified Bruce protocol.
Our results indicate that inflammatory indices [C-reactive protein (CRP), platelets] decreased in the taurine group in pre-exercise, post-supplementation and post-exercise, post-supplementation as compared with pre-exercise, pre-supplementation ( p < 0.05) whereas these indices increased in pre-exercise, post-supplementation and post-exercise, post-supplementation as compared with pre-exercise, pre-supplementation in the placebo group ( p < 0.05). Our results also show that atherogenic indices [Castelli's Risk Index-I (CRI-I), Castelli's Risk Index-II (CRI-II) and Atherogenic Coefficient (AC)] decreased in the taurine group in pre-exercise, post-supplementation and post-exercise, post-supplementation as compared with pre-exercise, pre-supplementation ( p < 0.05). No such changes were noted in the placebo group ( p > 0.05).
our results suggest that 2 weeks of oral taurine supplementation increases the taurine levels and has anti-atherogenic and anti-inflammatory effects prior to and following incremental exercise in HF patients.
本研究旨在探讨补充牛磺酸对心力衰竭（HF）患者在递增运动前后的抗动脉粥样硬化和抗炎作用。
左心室射血分数低于50%且根据纽约心脏协会分类处于功能II级或III级的HF患者被随机分为两组：（1）补充牛磺酸组；或（2）安慰剂组。牛磺酸组每天口服牛磺酸（500毫克）3次，共2周，并在补充期前后进行运动。安慰剂组遵循相同方案，但服用淀粉补充剂（500毫克）而非牛磺酸。递增多级跑步机测试采用改良的布鲁斯方案进行。
我们的结果表明，与运动前、补充前相比，牛磺酸组在运动前、补充后以及运动后、补充后的炎症指标[C反应蛋白（CRP）、血小板]下降（p<0.05），而安慰剂组在运动前、补充后以及运动后、补充后的这些指标与运动前、补充前相比升高（p<0.05）。我们的结果还表明，与运动前、补充前相比，牛磺酸组在运动前、补充后以及运动后、补充后的动脉粥样硬化指标[卡斯泰利风险指数-I（CRI-I）、卡斯泰利风险指数-II（CRI-II）和动脉粥样硬化系数（AC）]下降（p<0.05）。安慰剂组未观察到此类变化（p>0.05）。
我们的结果表明，口服牛磺酸2周可提高牛磺酸水平，并对HF患者在递增运动前后具有抗动脉粥样硬化和抗炎作用。
